That progress did not emerge spontaneously. It was built, trial by trial, on the evidence generated by patients who volunteered for clinical studies and by the clinicians, researchers, advocates, and communities who supported them. Each completed study has helped determine which therapies work best, refined screening and early detection strategies, and identified ways to help survivors live longer and better. The Alliance itself is a formidable research infrastructure: it unites more than 26,000 cancer specialists across 112 main institutions and 1,400 affiliates in the United States and Canada, operates as part of the National Clinical Trials Network, and serves as a leading research base for the NCI Community Oncology Research Program. Its work has produced multiple FDA approvals, influenced national treatment guidelines, and generated hundreds of high-impact publications. More than 40,000 participants have enrolled in Alliance studies, and its biospecimen repository now holds over 1.5 million samples collected across three decades, a resource that continues to fuel new discoveries.

Understanding who is at risk helps explain why this research pipeline matters. About 60 percent of prostate cancers are diagnosed in men aged 65 and older, and risk is elevated among men of African or Caribbean descent, tobacco smokers, and those with a family history of the disease. Because prostate cancer often produces no symptoms at all in its early stages, many cases are caught only through screening or incidental findings. Men who do experience warning signs, such as difficulty urinating, painful urination, or blood in the urine, are advised to consult a physician promptly. The silence of the disease in its most treatable phases is precisely why improved early detection tools remain a central research priority, and why trials that test new diagnostic and risk-stratification approaches can have consequences that ripple across millions of lives.

Among the Alliance’s current portfolio, several trials target the hardest clinical problems in prostate cancer care. One of the most intriguing is Alliance A031702, known as ICONIC, a phase II study led by Andrea Apolo, MD, of the National Cancer Institute. ICONIC is evaluating a three-drug combination, cabozantinib, nivolumab, and ipilimumab, for rare genitourinary cancers that have spread, including primary small cell carcinoma of the prostate. These unusual cancers often lack standardized treatment options, leaving patients with few alternatives. The scientific logic of the combination is deliberate: cabozantinib is a daily targeted pill that blocks enzymes driving tumor growth and the development of blood vessels that feed tumors, while nivolumab and ipilimumab are intravenous immunotherapies that release the brakes on the patient’s own immune system, allowing immune cells to attack cancer. By pairing these mechanisms, researchers hope to overcome the treatment resistance that has long characterized these rare malignancies.

Precision medicine takes center stage in Alliance A032102, the PREDICT trial, led by Rana McKay, MD, of the University of California San Diego. This phase II study asks a deceptively simple question: can genetic profiling match patients with metastatic prostate cancer to therapies that actually work against their tumors, improving outcomes compared with standard approaches? Participants first undergo DNA and RNA sequencing of tumor tissue or blood. A molecular tumor board then reviews the results and assigns each participant to a personalized treatment arm. Arm A receives valemetostat tosylate, an oral drug that inhibits the EZH1 and EZH2 proteins, altering tumor gene expression to slow growth. Arm B receives intravenous carboplatin combined with cabazitaxel, aimed at tumors carrying specific mutations such as alterations in TP53, RB1, or PTEN. Arm C receives one of several standard options, including targeted radiopharmaceutical therapy, chemotherapy, or novel anti-androgen agents such as abiraterone or enzalutamide. The trial embodies the growing conviction that the molecular anatomy of a tumor should dictate its treatment.

For men with newly diagnosed advanced disease, Alliance A032302, the ASPIRE trial, tackles a question of treatment intensity. Led by Deepak Kilari, MD, of Froedtert and the Medical College of Wisconsin, this phase III study is testing whether adding docetaxel, an established chemotherapy drug, to hormone therapy plus apalutamide, a next-generation androgen receptor inhibitor, can extend overall survival in metastatic castrate-sensitive prostate cancer. The primary endpoint is overall survival, the most demanding measure in oncology. Importantly, the investigators are also conducting genetic analyses to determine whether patients with mutations in TP53, PTEN, or RB1, genes associated with more aggressive disease, derive greater benefit from the intensified regimen. If the answer is yes, the trial could help physicians identify which patients truly need the added toxicity of chemotherapy and which can safely avoid it, a step toward more individualized frontline care.

Reducing side effects without sacrificing efficacy is the goal of Alliance A032304, the RECIPROCAL trial, co-led by Thomas Hope, MD, of the University of California San Francisco, and Deaglan McHugh of Memorial Sloan Kettering Cancer Center. The phase III study examines the timing of Lutetium-177 PSMA radioligand therapy, or RLT, now a standard of care for metastatic castration-resistant prostate cancer. In this approach, a radioactive molecule is attached to a drug that homes to prostate cancer cells and is injected into the bloodstream, delivering targeted radiation from within. While PSMA RLT improves survival, it can cause dry mouth, fatigue, and gastrointestinal problems. RECIPROCAL is testing whether, after the first two doses, additional treatment can be delayed until there is evidence of disease activity. If successful, the strategy could preserve the survival benefit while meaningfully improving quality of life, a trade-off that matters enormously to patients living with advanced disease.

Cancer care extends beyond attacking the tumor, and two Alliance studies reflect that broader vision. The DEFEND trial, led by Kathryn Schmitz, PhD, MPH, of UPMC Hillman Cancer Center and Jennifer Ligibel, MD, of Dana-Farber Cancer Institute, is testing whether a structured exercise program delivered entirely through telehealth can help patients receiving chemotherapy maintain physical function, reduce fatigue, and prevent disability. Meanwhile, Project Reach, a phase III trial led by Devon Noonan, PhD, MPH, FNP-B, of the Duke University School of Nursing, evaluates a text-based smoking cessation intervention for cancer survivors in rural communities, where access to specialized services is often limited. Because smoking worsens cancer outcomes and overall health, the trial seeks accessible, scalable ways to help survivors quit. Both studies recognize that survival is only meaningful if patients can live well during and after treatment.

Prevention and early detection round out the research agenda. Alliance A212102, led by Marie Wood, MD, of the University of Colorado School of Medicine, is building a blinded reference set of blood and tissue samples from people with and without cancer to help evaluate and advance multicancer early detection blood tests, with prostate cancer among the diseases represented. Such reference sets are essential for determining how well these emerging liquid biopsy tests actually perform before they reach widespread clinical use. Separately, the AYA Access Study, led by Angela Bradbury, MD, of the University of Pennsylvania Abramson Cancer Center, is exploring whether online genetic education and at-home genetic testing can make genetic risk information more accessible to adolescents and young adults with a history of cancer, dismantling barriers that keep young patients from genetic services that could shape their long-term care.

During Prostate Cancer Awareness Month, the Alliance’s message is ultimately about momentum and participation. Every clinical trial adds to what science knows, every participant helps move that science forward, and every discovery brings medicine closer to a future with fewer diagnoses and more survivors. The decline in prostate cancer mortality since 1993 stands as proof that sustained, evidence-based research changes outcomes on a population scale. The trials now underway, spanning immunotherapy combinations, genomic matching, treatment intensification, radiation timing, exercise medicine, smoking cessation, and early detection blood tests, suggest that the next chapter of progress is already being written, one enrolled patient at a time.

Subject of Research: Clinical trials advancing prostate cancer early detection, treatment, and survivorship

Article Title: Prostate Cancer Awareness Month: How Alliance Clinical Trials help reshape early detection and improve treatments

Article References: Prostate Cancer Awareness Month: How Alliance Clinical Trials help reshape early detection and improve treatments. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, clinical trials, Alliance for Clinical Trials in Oncology, early detection, immunotherapy, precision medicine, radioligand therapy, docetaxel, genetic profiling, cancer survivorship, multicancer early detection, Prostate Cancer Awareness Month